MedPath

Angion Biomedica Corp.

Angion Biomedica Corp. logo
🇺🇸United States
Ownership
Public, Subsidiary
Established
1998-01-01
Employees
101
Market Cap
-
Website
http://www.angion.com

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

Phase 1
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Drug: Placebo
First Posted Date
2022-05-24
Last Posted Date
2022-06-10
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
20
Registration Number
NCT05387785

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

Phase 1
Conditions
Hemodialysis
Interventions
First Posted Date
2021-07-12
Last Posted Date
2021-07-15
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
16
Registration Number
NCT04958187
Locations
🇺🇸

Hennepin County Medical Center (HCMC), Minneapolis, Minnesota, United States

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Phase 2
Conditions
Proteinuria
Glomerular Disease
Interventions
Drug: Placebo
First Posted Date
2021-06-25
Last Posted Date
2022-03-23
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
100
Registration Number
NCT04939116
Locations
🇺🇸

The Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

University of Vermont Medical Center, Burlington, Vermont, United States

🇦🇺

John Hunter Hospital, New Lambton, New South Wales, Australia

and more 24 locations

A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777

Phase 1
Conditions
Healthy
Interventions
Drug: carbon-14-[14C]-ANG-3777
First Posted Date
2021-06-18
Last Posted Date
2021-06-18
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
6
Registration Number
NCT04931524
Locations
🇬🇧

Quotient Sciences, Nottingham, Nottinghamshire, United Kingdom

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Phase 1
Conditions
Healthy Volunteer
Interventions
Drug: ANG-3777 (Therapeutic Dose)
Drug: Placebo
Drug: ANG-3777 (Supra-therapeutic Dose)
First Posted Date
2021-05-24
Last Posted Date
2021-06-01
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
48
Registration Number
NCT04898907
Locations
🇺🇸

Quotient Sciences, Miami, Florida, United States

Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia

Phase 2
Conditions
COVID-19
Pneumonia
Interventions
Drug: Standard of Care (SOC) + ANG-3777
Drug: Standard Of Care (SOC) + Placebo
First Posted Date
2020-07-07
Last Posted Date
2021-04-15
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
100
Registration Number
NCT04459676
Locations
🇧🇷

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP), Ribeirão Preto, Brazil

🇧🇷

Pontifícia Universidade Catolica de Campinas, Campinas, Sao Paulo, Brazil

🇧🇷

UPCLIN - Faculdade de Medicina da UNESP Campus de Botucatu, Botucatu, Brazil

and more 7 locations

ANG-3070 in Healthy Adult Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo oral capsule
First Posted Date
2019-12-12
Last Posted Date
2021-07-21
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
97
Registration Number
NCT04196179
Locations
🇦🇺

Nucleus Network, VIC, Melbourne, Australia

Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass

Phase 2
Conditions
Acute Kidney Injury
Interventions
Drug: Placebo
First Posted Date
2016-05-13
Last Posted Date
2021-07-15
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
275
Registration Number
NCT02771509
Locations
🇬🇪

Tbilisi Heart Center, Tbilisi, Georgia

🇬🇪

Acad. G. Chapidze Emergency Cardiology Center, Tbilisi, Georgia

🇺🇸

Bryan Heart, Lincoln, Nebraska, United States

and more 37 locations

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

Phase 3
Conditions
Delayed Graft Function
Interventions
Other: Placebo
First Posted Date
2015-06-18
Last Posted Date
2021-06-03
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
253
Registration Number
NCT02474667
Locations
🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

and more 27 locations

Study on Delayed Graft Function Using Paired Kidneys

Phase 2
Conditions
Delayed Graft Function
Interventions
Drug: Normal Saline
First Posted Date
2012-03-23
Last Posted Date
2016-02-22
Lead Sponsor
Angion Biomedica Corp
Target Recruit Count
12
Registration Number
NCT01561599
Locations
🇳🇱

Maastricht University Medical Center, Minderbroedersberg, Maastricht, Netherlands

🇪🇸

Hospital Clínico San Carlos, San Carlos, Madrid, Spain

🇬🇧

The Newcastle Upon Tyne Hospital, Newcastle, metropolitan county of Tyne and Wear, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath